AN2 Therapeutics jumps after GSK collaboration to develop tuberculosis treatment

AN2 Therapeutics

10/11/2025 12:46

** Shares of biopharma firm AN2 Therapeutics ANTX.O rise 12.2% to $1.24 premarket

** Company enters a collaboration agreement with GSK GSK.L to develop new therapies for tuberculosis

** Under the agreement, the Gates Foundation will provide a third year of funding to support AN2’s work within the collaboration

** As of last close, stock down 17.4% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))